Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
Gastrointest Endosc. 2012 Apr;75(4):712-8. doi: 10.1016/j.gie.2011.11.036. Epub 2012 Jan 28.
Fully covered self-expandable metal stents (FCSEMSs) are increasingly being used for malignant and benign strictures. Particularly in the latter, FCSEMSs are known for their high migration rates. A new FCSEMS with a dog-bone shape and internal covering was developed to reduce migration risk.
To evaluate recurrent dysphagia and safety of the new FC stent in benign and malignant esophageal disorders.
Prospective follow-up study.
Tertiary referral center.
Between November 2009 and February 2011, 48 consecutive patients (mean age 61 years, range 28-81 years) underwent FC stent placement for malignant (n = 33) or benign (n = 15) dysphagia.
FC stent placement.
Recurrent dysphagia and complications.
Indications for FC stent placement included esophageal cancer (n = 28), extrinsic malignant compression (n = 4), recurrent malignancy after esophagectomy (n = 1), and refractory benign esophageal stricture (n = 15). In malignant strictures, recurrent dysphagia occurred in 5 patients (15%) because of stent migration (n = 3), tissue overgrowth (n = 1), and acute edema (n = 1). In benign strictures, stents were prematurely removed in 9 (60%) patients because of stent migration (n = 5), tissue overgrowth (n = 3), and pain (n = 1). Recurrent dysphagia occurred in all patients after stent removal. Major complications occurred in 10 patients (30%) with malignant strictures and in 3 patients (20%) with benign strictures and included severe pain and/or vomiting (n = 8), fistula formation (n = 2), bleeding (n = 2), and aspiration pneumonia (n = 1).
Nonrandomized study design.
Although the new FC stent effectively treats malignant dysphagia, it is associated with substantial major complications. In patients with refractory benign esophageal strictures, recurrent dysphagia occurs rapidly after removal of the new FC stent.
完全覆膜自膨式金属支架(FCSEMS)越来越多地用于治疗恶性和良性狭窄。特别是在后者中,FCSEMS 以高迁移率而闻名。一种具有狗骨形状和内部覆盖物的新型 FCSEMS 已被开发出来,以降低迁移风险。
评估新型 FC 支架在良性和恶性食管疾病中的复发性吞咽困难和安全性。
前瞻性随访研究。
三级转诊中心。
2009 年 11 月至 2011 年 2 月期间,48 例连续患者(平均年龄 61 岁,范围 28-81 岁)因恶性(n=33)或良性(n=15)吞咽困难接受 FC 支架置入术。
FC 支架置入术。
复发性吞咽困难和并发症。
FC 支架置入的适应证包括食管癌(n=28)、外压性恶性压迫(n=4)、食管癌切除术后复发恶性肿瘤(n=1)和难治性良性食管狭窄(n=15)。在恶性狭窄中,5 例患者(15%)因支架迁移(n=3)、组织过度生长(n=1)和急性水肿(n=1)而出现复发性吞咽困难。在良性狭窄中,9 例(60%)患者因支架迁移(n=5)、组织过度生长(n=3)和疼痛(n=1)而提前取出支架。支架取出后所有患者均出现复发性吞咽困难。10 例恶性狭窄患者(30%)和 3 例良性狭窄患者(20%)出现主要并发症,包括严重疼痛和/或呕吐(n=8)、瘘形成(n=2)、出血(n=2)和吸入性肺炎(n=1)。
非随机研究设计。
虽然新型 FC 支架有效治疗恶性吞咽困难,但与严重的主要并发症相关。对于难治性良性食管狭窄患者,新型 FC 支架取出后迅速出现复发性吞咽困难。